Owen: The Promise of Outsourcing
Executive Summary
After two years of tough times, Owen is now poised to grow again with new management and a climate ripe for outsourcing.
You may also be interested in...
Pipeline Watch: Japan Dominates 25 New Approvals, Plus Six Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
What’s Next? Five Things To Look Out For In October
A busy October will include planned biosimilar launches and key appointments for the off-patent sector.
Sandoz: Big Cap Biosimilar Rivals Lack Clarity On Commitment
Sandoz has had its say on its biosimilar rivals with largely branded portfolios, as well as the recent EMA statement supporting biosimilar interchangeability.